Biotech Startups

Ramona Optics builds parallelized multi-camera array microscope systems for imaging and analyzing small model organisms and cell cultures in multi-well plates. Its products serve research labs studying zebrafish behavior, morphology, and functional biology, as well as cell confluency and organoids.

2 investors

2 investors

Rani Therapeutics develops oral drug delivery technology using robotic capsules to replace injectable biotherapeutics, addressing the challenge of delivering biologics through the gastrointestinal tract without needles. The company targets patients with chronic conditions who currently require painful injections.

2 investors

Rapid Novor develops protein sequencing software and methods for antibody analysis, combining bioinformatics and mass spectrometry technology. The company specializes in proteomics services for clients requiring high-throughput antibody sequencing.

2 investors

Rapport is a biopharmaceutical company developing novel therapeutics. The company is led by a team with extensive experience in drug discovery, clinical development, and commercialization across neuroscience and rare disease indications.

2 investors

RareCan provides cancer treatment and clinical trial access tailored to individual patients, with a focus on improving outcomes for people diagnosed with rare cancers.

2 investors

Rarity Bioscience develops superRCA, a molecular detection technology that identifies DNA mutations with exceptional sensitivity for precision medicine applications. The company commercializes diagnostic assays and kits for clinical and research settings, with initial focus on leukemia and cancer detection.

2 investors

Raycaster is an AI workspace that reviews and revises regulatory and clinical documents (protocols, reports, modules, quality documentation) for biopharma companies to keep submissions aligned with scientific changes. It works on native document formats and traces impacts across interconnected dossiers for IND through lifecycle management.

2 investors

Ray Therapeutics develops optogenetics gene therapy treatments for blinding diseases using advanced biotechnology. The company focuses on addressing unmet patient needs in ophthalmology through gene therapy innovation.

2 investors

RD Biotech provides a compact, high-throughput automated diagnostic testing platform that processes up to 1,440 samples in 24 hours across reproductive health, respiratory infections, bloodborne diseases, and enteroviruses. The system is designed for clinical laboratories and diagnostic facilities seeking space-efficient batch processing with flexible sample loading.

2 investors

RealSeq Biosciences develops RNA fragmentomics technology for advanced diagnostics, enabling detection and analysis of RNA fragments to discover new biomarkers and provide deeper insights into disease. The company serves the healthcare and diagnostics industry by unlocking previously inaccessible biological information from RNA.

2 investors

Reaxbio develops a chemoproteomics platform that identifies and targets novel protein sites for drug discovery across disease-relevant biological contexts. The platform enables small molecule discovery for virtually any protein using proprietary chemical tools and high-throughput screening capabilities.

2 investors

Recor Medical develops the Paradise Ultrasound Renal Denervation system, a therapy that uses ultrasound technology to lower blood pressure in patients with hypertension. Founded in 2009 and now part of Otsuka Medical Devices, the company brings its hypertension treatment to physicians and patients worldwide.

2 investors

RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases. The company uses high-throughput technologies and structural/disease biology to engineer and select antibody candidates for liquid and solid tumors and for inflammatory and autoimmune conditions.

2 investors

Reduced Foods uses a proprietary fermentation and koji-based "Waste-2-Taste" technology to upcycle food side streams into flavour ingredients that deliver umami, kokumi, and maillard notes as clean-label alternatives to MSG, yeast extracts, and hydrolyzed vegetable proteins. The company serves industrial food producers and positions its ingredients as lower-carbon, sustainable options.

2 investors

Reflector provides a machine learning platform that predicts functional responses of small molecules across diverse cellular contexts to prioritize drug candidates earlier in the discovery process. The tool helps pharmaceutical teams assess phenotypic effects, identify off-target liabilities, and classify mechanisms of action before committing to expensive downstream experiments.

2 investors

Regor is a drug discovery company that uses a computational platform (rCARD) to identify and optimize preclinical small-molecule candidates in metabolism, oncology, and immunology, which it licenses to pharmaceutical companies for clinical development. Its pipeline includes RGT-075, an oral GLP-1R agonist for obesity and type 2 diabetes, and next-generation CDK inhibitors for breast cancer.

2 investors

Regulus Therapeutics was a San Diego-based clinical-stage biopharmaceutical company developing oligonucleotide drugs that inhibit disease-causing microRNAs. Its lead program, farabursen, targeted miR-17 for treating autosomal dominant polycystic kidney disease.

2 investors

Remedium Bio is a biotech company developing gene therapy and biologic treatments for osteoarthritis and other rheumatology and metabolic conditions, drawing on research into cartilage regeneration and the FGF18 protein. Its work targets diseases such as osteoarthritis, arthritis, and diabetes-related metabolic conditions.

2 investors

Remedy Pharmaceuticals is a pharmaceutical company developing Cirara, an investigational drug studied in clinical trials for patients who have suffered a stroke. It focuses on treatments for serious neurological conditions.

2 investors

Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer. Its lead clinical candidate, RPT1G, is a hyperbolic inhibitor designed to reduce NAMPT activity while avoiding the toxicity that has limited earlier attempts.

2 investors

remynd develops first-in-class oral treatments to restore and preserve neuronal function in patients with age-related neurodegenerative diseases such as Alzheimer's and Huntington's, and runs a discovery program targeting mitochondrial dysfunction in ALS. It also operates a contract research organization (CRO) that uses proprietary mouse models to help pharmaceutical companies in the US, Europe and Japan assess experimental neurodegenerative disease treatments.

2 investors

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD). Its pipeline targets the underlying biology of ADPKD across a range of mutations with the goal of halting and reversing disease progression.

2 investors

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.

2 investors